A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment

Ja Min Byun, Ho Young Kim, Seung Hyun Nam, Ho Jin Shin, Seulki Song, Jinny Park, Sang Hoon Han, Yong Park, Young Jin Yuh, Yeung Chul Mun, Young Rok Do, Sang Kyun Sohn, Sung Hwa Bae, Dong Yeop Shin, Sung Soo Yoon

Research output: Contribution to journalArticlepeer-review

Abstract

As the discussion of first-line anagrelide treatment is ongoing, we aimed to prospectively examine the efficacy and safety of anagrelide in cytoreduction therapy-naïve high risk essential thrombocythemia (ET) patients in Korea. Seventy patients from 12 centers were treated with anagrelide monotherapy for up to 8 weeks, followed up until 24 months. At week 8, 50.0% of the patients were able to achieve platelet < 600 x 109/L, and by 12 months, 55/70 (78.6%) patients stayed on anagrelide, and 40.0% patients showed platelet normalization. 14 patients required additional hydroxyurea (HU) for cytoreduction. The median daily dose of needed HU was 500mg (range 250mg – 1500mg). The efficacy was independent of the somatic mutation status. There were 4 thromboembolic events and 7 bleeding events during the follow-up period. The most common adverse events associated with anagrelide use were headache, followed by palpitation/chest discomfort, edema and generalized weakness/fatigue. 7 patients wished to discontinue anagrelide treatment due to adverse events (3 due to headache; 2 due to edema; 1 due to palpitation and 1 due to skin eruption). All in all, first-line anagrelide treatment showed a favorable response with tolerable safety profiles regardless of somatic mutation status.

Original languageEnglish
Article number989984
JournalFrontiers in Oncology
Volume12
DOIs
StatePublished - 23 Nov 2022

Bibliographical note

Publisher Copyright:
Copyright © 2022 Byun, Kim, Nam, Shin, Song, Park, Han, Park, Yuh, Mun, Do, Sohn, Bae, Shin and Yoon.

Keywords

  • Anagrelide
  • essential thrombocythemia
  • high risk
  • myeloproliferative neoplasms
  • phase IV clinical trial

Fingerprint

Dive into the research topics of 'A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment'. Together they form a unique fingerprint.

Cite this